Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 2Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 56Leukemia, Myeloid, Acute 38Breast Neoplasms 38Lymphoma, Large B-Cell, Diffuse 37Multiple Myeloma 31Lymphoma, Non-Hodgkin 30Burkitt Lymphoma 30Lymphoma 28Myelodysplastic Syndromes 25Triple Negative Breast Neoplasms 23Lymphoma, B-Cell 22Hematologic Neoplasms 22Recurrence 21Lymphoma, Follicular 20Melanoma 16Leukemia, Lymphocytic, Chronic, B-Cell 15Leukemia 14Ovarian Neoplasms 13Neoplasm Metastasis 13Hodgkin Disease 13Neoplasms 12Leukemia, Biphenotypic, Acute 12Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 11Pancreatic Neoplasms 11Neuroblastoma 11Leukemia, Myelomonocytic, Chronic 11Lymphoma, Mantle-Cell 10Graft vs Host Disease 10Carcinoma, Non-Small-Cell Lung 10Sarcoma 9

Interventions

Injections 16pembrolizumab 6Bevacizumab 6Paclitaxel 4Leucovorin 4Fluorouracil 4Carboplatin 4fludarabine 3Pemetrexed 3Oxaliplatin 3Capecitabine 3toripalimab 2sotorasib 2Immune Checkpoint Inhibitors 2Fulvestrant 2Drug Therapy 2Docetaxel 2Cyclophosphamide 2Cisplatin 2130-nm albumin-bound paclitaxel 2zimberelimab 1trifluridine tipiracil drug combination 1trametinib 1tislelizumab 1sacituzumab govitecan 1palbociclib 1osimertinib 1olaparib 1lazertinib 1fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Advanced Solid Tumors × Cyclophosphamide × Clear all
NCT06773091 2026-04-06

NKSOLID

Shanghai NK Cell Technology Co., LTD

Phase 1 Recruiting
76 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT05881525 2025-07-16

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

TCRCure Biopharma Ltd.

Phase 1 Recruiting
18 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡